Therapeutics News and Research

RSS

FINGERS-7B to eradicate Alzheimer's symptoms

Alzheimer's disease is best addressed as early as possible, ideally before symptoms become apparent. To enable early, accurate risk prediction both for individuals and whole populations, a team of AI researchers, physicians, and scientists centered at MIT has released FINGERS-7B, the first AI foundation model built to make Alzheimer's preventable.

28 Apr 2026

Lipid pathways driving diabetes and heart disease risk in South Asians

Identifying lipid-linked genetic pathways in Asian Indians offers insights into diabetes and heart disease, crucial for developing ancestry-specific therapies.

28 Apr 2026

New cord blood approach boosts survival in blood disease patients

A new way of using umbilical cord blood for treating blood diseases could make the treatment more accessible to patients who need a stem cell transplant.

27 Apr 2026

Twice-yearly blood pressure treatment could reshape hypertension care, but doctors warn against a “fire-and-forget” approach

Long-acting RNA interference therapy for hypertension could shift blood pressure control from daily pill-taking to scheduled, system-led protection. But the authors warn that this “vaccine-like” model must preserve lifestyle support, monitoring, and follow-up to avoid clinical disengagement.

27 Apr 2026

Scientists seek to reverse neurodegeneration by eliminating harmful RNA pollution

Researchers at University of California San Diego School of Medicine, the Salk Institute and Sanford Burnham Prebys have received a four-year, $13 million award from the California Institute for Regenerative Medicine (CIRM) to investigate how to reverse age-related neurodegeneration by eliminating what the researchers call "RNA pollution" in aging neurons.

27 Apr 2026

Bacterial vesicles emerge as powerful tools against antibiotic resistance

Antibiotic resistance is making bacterial infections harder to treat, demanding new therapeutic strategies. A new review highlights bacterial extracellular vesicles (BEVs) as promising nanoscale tools that can kill pathogens, block infection, enhance vaccines, and deliver drugs.

25 Apr 2026

Intercellular heme transfer pathway sustains red blood cell production under stress

Scientists have long been puzzled by how maturing red blood cells manage to produce all the hemoglobin they need to carry oxygen to tissues, even after shedding the vital structures they need to produce it.

25 Apr 2026

Scientists discover immune sentinel cells within skin hair follicles

Researchers at the School of Medicine at the University of California, Riverside have discovered previously unrecognized immune surveillance structures in the skin.

25 Apr 2026

Air quality in infancy may fundamentally shape long-term immune development

Ambient air pollution is associated with respiratory infection burden in the first year of life, according to preliminary findings from the Immune Development in Early Life (IDEaL) Rome Cohort. Findings from the cohort will be presented during the Pediatric Academic Societies (PAS) 2026 Meeting, taking place April 24-27 in Boston.

24 Apr 2026

Microplastics in the liver may drive global liver disease rates

There is considerable evidence that microplastics and nanoplastics are present in the livers of humans, and wild animal populations on land and in the ocean.

23 Apr 2026

New gene therapy improves hearing in patients with rare genetic deafness

A new international study co-led by investigators from Mass General Brigham and the Eye & ENT Hospital of Fudan University shows that a gene therapy for a rare form of genetic deafness successfully restored hearing in most participants, with results lasting up to 2.5 years.

23 Apr 2026

Experimental drug kills aggressive breast cancer by toxic fat buildup

An experimental drug targeting triple-negative breast cancer overwhelms cancer cells with toxic fats, according to new tests on human-derived tumors in mice.

22 Apr 2026

Global experts highlight new strategies to target human aging

A new meeting report was published in Volume 18 of Aging-US on April 6, 2026, titled "Toward actionable interventions in human aging (12th ARDD meeting, 2025)."

22 Apr 2026

Gut microbiome characteristics predict treatment response in IBS-D patients

In a new study published in Clinical Gastroenterology and Hepatology, the low FODMAP diet and the antibiotic rifaximin provided similar and significant relief for patients with irritable bowel syndrome with diarrhea (IBS-D).

22 Apr 2026

Immunotherapy drug helps bladder cancer patients avoid major organ removal

A drug that helps the immune system find cancer cells also helps patients avoid having their bladders surgically removed (cystectomy), a new study shows.

22 Apr 2026

New guideline recommends combined therapies for chronic insomnia treatment

A new clinical practice guideline from the American Academy of Sleep Medicine provides evidence‑based recommendations on the combined use of behavioral‑psychological and pharmacological therapies to treat chronic insomnia disorder in adults.

21 Apr 2026

Epigenome proteins shape dynamic gene expression beyond simple on-off

A new study finds the proteins responsible for controlling which genes are expressed in a genome do more than simply turn a gene on or off.

21 Apr 2026

APC-deficient cancer cells rely on single enzyme for survival

A newly published study reports that APC-deficient cancer cells may depend on a single metabolic enzyme for survival, revealing a potential strategy for selectively targeting tumours associated with one of the most common mutations in colorectal cancer.

20 Apr 2026

Trial shows safety of novel KIR-CAR T therapy in solid tumors

An innovative type of CAR T cell therapy, called KIR-CAR, was shown to be safe, with increasing efficacy corresponding to higher doses of the investigational treatment in nine patients with advanced ovarian cancer, mesothelioma or cholangiocarcinoma (bile duct cancer), according to an early report from an ongoing Phase I dose-escalation clinical trial.

20 Apr 2026

Single CAR T infusion shows strong response in smoldering multiple myeloma patients

A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma, according to results from CAR-PRISM, a phase II clinical trial, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.

20 Apr 2026